Awakn Life Sciences Initiates Follow-on Behavioral Study to Focus on Gambling Disorder

Awakn Life Sciences has announced that they have initiated a larger behavioral addiction study investigating ketamine as a treatment for Gambling Disorder. The larger study announced today will include 42 patients who are suffering from Gambling Disorder and will see participants undergo a memory reactivation procedure, which is designed to weaken the link between reward and addiction memories. The larger placebo-controlled study will be the first investigation globally to explore this technique to treat Gambling Disorder.

Category Press Release
Published in Awakn Life Sciences

Companies Featured

Awakn Life Sciences
AWAKN Life Sciences aims to bring psychedelics therapy to the UK. Under this company fall three arms; psychedelic research, clinic platform, and practitioner training.